Nasal administration

FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season

Retrieved on: 
Tuesday, August 31, 2021
FDA, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Public Health England, Aspirin, Sore throat, AAP, Virus, Metabolism, Influenza, Science, CDC, ACIP, American Academy, Food, Person, Vaccine, Biopharmaceutical, PHE, Pediatrics (journal), Heart, Allergy, Senior, Locator, Public health, Immunology, 2020–2021 United States flu season, Nose, Patient, Fever, Food and Drug Administration, Selected Patient Information Resources in Asian Languages, Vaccination, FDA, Anaphylaxis, Nasal administration, Nasal congestion, LAIV, Pharmaceutical industry

AstraZeneca today announced that FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses are now available in the US for the 2021-2022 influenza season.

Key Points: 
  • AstraZeneca today announced that FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses are now available in the US for the 2021-2022 influenza season.
  • FLUMIST QUADRIVALENT, the only Food and Drug Administration (FDA)-approved nasal-spray flu vaccine, is indicated for people ages 2 through 49.
  • The CDC continues to stress the importance of receiving a yearly flu vaccine, citing vaccination as the most effective protection against seasonal flu infection.
  • Since FLUMIST QUADRIVALENT is the only FDA-approved flu vaccine to use a needle-free nasal spray administrative technique, it may be preferred by eligible patients.

Global Topical Drug Delivery Market 2021-2026: Products, Route of Administration, End-user - Competitive Analysis, Impact of COVID-19, Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Health, Pharmaceutical, Health sciences, Routes of administration, Pharmacology, Medicine, Drug delivery, Route of administration, Topical medication, Transdermal, Nasal administration, Rectal administration, Dosage form

The Global Topical Drug Delivery Market is estimated to be worth USD 95.6 Billion in 2021 and is expected to reach USD 124.9 Billion by 2026, growing at a CAGR of 5.5%.

Key Points: 
  • The Global Topical Drug Delivery Market is estimated to be worth USD 95.6 Billion in 2021 and is expected to reach USD 124.9 Billion by 2026, growing at a CAGR of 5.5%.
  • Higher preference for alternative modes of drug delivery is hindering market growth.
  • Delivery of biologics through the transdermal route and self-administration and home care are some of the opportunities for the market players to grow.
  • By Route of Administration, the market is classified as Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery and Nasal Drug Delivery.

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Retrieved on: 
Friday, July 9, 2021
Health sciences, Health, Medicine, Drug discovery, Rintatolimod, AIM ImmunoTech, Common cold, Rhinovirus, Antiviral drug, Therapy, Live attenuated influenza vaccine, Nasal administration

OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Key Points: 
  • OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
  • In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics.
  • This Phase 2a study will come in the wake of AIMs recent announcement that all subjects have completed treatment in the companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement for SipNose Cribriform Targeted Device

Retrieved on: 
Tuesday, June 1, 2021
Biotechnology, Medical devices, Other Health, Health, Pharmaceutical, Health sciences, Clinical medicine, Dosage forms, Nasal administration, Yokneam, Cribriform, Glaucoma, Health, ST266, Noveome Biotherapeutics, Inc., SipNose Cribriform Targeted Device, SipNose Ltd., ST266, NOVEOME BIOTHERAPEUTICS, INC., SIPNOSE CRIBRIFORM TARGETED DEVICE, SIPNOSE LTD.

Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).

Key Points: 
  • Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).
  • Noveome and SipNose have established a great working relationship which has enabled a successful collaboration, said William J.
  • Noveome recently closed enrollment and completed the treatment phase of its Phase 1 safety study using the SipNose device to administer ST266 to Glaucoma Suspect patients.
  • Based in Israel, SipNose is a clinical stage nasal delivery company that has developed an innovative Cribriform Targeted Device for non-invasive delivery of pharmaceuticals.

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medicine, Health sciences, Nose, Dosage forms, Routes of administration, Sensory organs, Nasal administration, Nasal cavity, Drug delivery, Nasal

b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.

Key Points: 
  • b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.
  • The device will be used to deliver the Company\xe2\x80\x99s drug candidate, PRV-002 for concussion treatment and is designed to enhance bio-distribution to the brain.
  • The nasal device will be used in phase 1 clinical trials being scheduled in Australia this summer.
  • \xe2\x80\x9cThis innovation will provide more uniform drug distribution to the nasal cavity while enhancing availability to the brain.

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Retrieved on: 
Friday, May 14, 2021
Health sciences, Clinical medicine, Medicine, Audiology, Occupational safety and health, Auditory perception, Symptoms, Tinnitus, XC2, Ear, Nasal administration, Auris

They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.

Key Points: 
  • They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.
  • \xe2\x80\x9cWe look forward to completing the TRAVERS trial later in 2021 and to advancing the AM-125 program further.
  • There is a strong medical need for a novel drug in this area, with e.g.
  • In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi\xc2\xae (AM-111) for acute inner ear hearing loss and Keyzilen\xc2\xae (AM-101) for acute inner ear tinnitus.

Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Neuroscience, Clinical medicine, Neurotechnology, Neuropsychology, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Nasal administration, Neurofeedback, Neuromodulation

"\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.

Key Points: 
  • "\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.
  • "Since opening our clinics less than 3 years ago, we have administered over 3,000 Intravenous Ketamine Infusionsand over 60 Intranasal Ketamine treatments.
  • Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression.
  • "\nThe clinic is to be operated as a joint venture, owned equally by the Company and NMC.

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Retrieved on: 
Thursday, April 22, 2021
Health, Infectious diseases, Surgery, General Health, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Psychoactive drugs, Euphoriants, Ketones, Analgesics, General anesthetics, Enkephalin, Nasal administration, Ketamine, Chronic pain, Torreya, Virpax Pharmaceuticals, TORREYA, VIRPAX PHARMACEUTICALS

Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.

Key Points: 
  • Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.
  • We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, capital markets, licensing, and asset sale transactions.
  • Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence.
  • Envelta\xe2\x84\xa2 is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

Nasus Pharma Announces Positive Results in Pivotal Trial of FMXIN001 Naloxone Powder-Based Nasal Spray for the Treatment of opioid overdose

Retrieved on: 
Tuesday, April 13, 2021
Clinical medicine, Medicine, Drugs, Medical emergencies, Morphinans, Opioid antagonists, Tertiary alcohols, Substance abuse, Naloxone, Opioid overdose, Nasal administration, Drug overdose

The rapid rise in Naloxone levels in the blood may be advantageous for reversing respiratory depression in opioid overdose.

Key Points: 
  • The rapid rise in Naloxone levels in the blood may be advantageous for reversing respiratory depression in opioid overdose.
  • We are focused on our NDA submission later this year with an objective to commercialized FMXIN001 in 2022.
  • "\nNasus Pharma IP protectedpowder-based composition for intranasal delivery is comprised of uniform spherical API\'s and acarrier approved for inhalations.
  • Nasus\'s portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.\n'

Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate

Retrieved on: 
Monday, March 22, 2021
Health sciences, Medicine, Clinical medicine, Medical research, Nasal administration, COVID-19 vaccine, Nasal vaccine

GAITHERSBURG, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide leader in nasal spray pharmaceuticals, to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced today that it has retained Summit Biosciences, a world-wide leader in nasal spray pharmaceuticals, to manufacture a metered nasal spray presentation of AdCOVID, its intranasal COVID-19 vaccine candidate.
  • As we continue to build our manufacturing consortium and progress the development of AdCOVID, we are pleased to partner with Summit Biosciences to manufacture AdCOVID in a customized multidose nasal spray delivery device.
  • In addition, Altimmune will continue to produce a single dose presentation of AdCOVID to provide alternative forms of administration.
  • Gregory Plucinski, President and COO, Summit Biosciences, said, I am pleased that Altimmune, a recognized leader in intranasal vaccine development, selected Summit in this exciting endeavor.